Table 1.
Characteristics of the Study Population by Human Immunodeficiency Virus Serostatus
| Characteristic | WWH (n = 928) |
WWOH (n = 381) |
P Value |
|---|---|---|---|
| Sociodemographic | |||
| Age, y, median (IQR) | 51 (44–54) | 48 (41–54) | .01 |
| Race/ethnicity | .18 | ||
| Black | 74% | 75% | |
| White | 10% | 7% | |
| Hispanic | 12% | 13% | |
| Other | 4% | 5% | |
| Lifestyle | |||
| Alcohol use | <.001 | ||
| None | 52% | 43% | |
| Light | 39% | 41% | |
| Moderate | 3% | 4% | |
| Heavy | 6% | 12% | |
| Current smoking | 36% | 43% | .03 |
| Current marijuana use | 20% | 26% | .02 |
| Ever injection drug use | 2.6% | 5.0% | .03 |
| Metabolic | |||
| BMI, kg/m2, median (IQR) | 30 (26–36) | 32 (27–37) | .15 |
| Waist circumference, cm, median (IQR) | 99 (89–111) | 100 (88–113) | .81 |
| HOMA-IR, median (IQR) | 2.1 (1.3–4.0) | 1.8 (1.1–3.3) | .047 |
| Diabetes mellitus | 19% | 21% | .57 |
| On HTN medication | 47% | 47% | .87 |
| On antidepressant medication | 27% | 17% | <.001 |
| Liver-related | |||
| AST, U/L, median (IQR) | 19 (16–24) | 17 (14–20) | <.001 |
| ALT, U/L, median (IQR) | 15 (12–21) | 14 (11–18) | <.001 |
| CAP, dB/m, median (IQR) | 247 (209–290) | 249 (206–283) | .68 |
| Liver stiffness, kPa, median (IQR) | 5.1 (3.9–6.7) | 4.9 (3.9–6.2) | .21 |
| HCV Ab positivea | 8% | 4% | .01 |
| HIV-related | |||
| Undetectable HIV RNA | 72% | … | |
| CD4 current, cells/µL, median (IQR) | 650 (435–869) | … | |
| CD4 nadir, cells/µL, median (IQR) | 223 (103–360) | … | |
| History of clinical AIDS | 30% | … | |
| Current ARV use | 90% | … | |
| NNRTI | 30% | … | |
| PI | 26% | … | |
| INSTI | 48% | … | |
Data are presented as percentage unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; ARV, antiretroviral; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; HCV Ab, hepatitis C virus antibody; HIV, human immunodeficiency virus; HOMA-IR, homeostatic model assessment of insulin resistance; HTN, hypertension; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; WWH, women with HIV; WWOH, women without HIV.
a
With no history of positive HCV RNA.